This combination therapy selectively acts on CLDN3/4 overexpressing tumors, in vitro and in vivo, thus improving PCa prognosis and contributing to the local control of PCa, especially in unresectable or refractory PCa (92). Here, CLDN3 is linked to posterior cortical atrophy.